THIRD-PARTY TESTING DOCUMENTATION ON EVERY BATCHDOMESTIC SHIPPING · 5–7 BUSINESS DAYS AFTER PROCESSINGSECURE ENCRYPTED CHECKOUTFOR RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USETHIRD-PARTY TESTING DOCUMENTATION ON EVERY BATCHDOMESTIC SHIPPING · 5–7 BUSINESS DAYS AFTER PROCESSINGSECURE ENCRYPTED CHECKOUTFOR RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USETHIRD-PARTY TESTING DOCUMENTATION ON EVERY BATCHDOMESTIC SHIPPING · 5–7 BUSINESS DAYS AFTER PROCESSINGSECURE ENCRYPTED CHECKOUTFOR RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE
Research Guide

CJC-1295 & Ipamorelin Synergy

A technical overview of the molecular mechanisms and common laboratory research protocols behind the CJC-1295 + Ipamorelin peptide blend — one of the most widely studied growth hormone secretagogue combinations in preclinical research.

GHRH AnalogGhrelin MimeticResearch Use Only

1. Molecular Overview

CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH 1-29), modified at four positions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). It acts on the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary, stimulating cAMP-dependent synthesis and pulsatile release of growth hormone (GH).

Ipamorelin is a selective pentapeptide ghrelin receptor (GHS-R1a) agonist. Unlike earlier GHRPs, Ipamorelin does not appreciably elevate cortisol, prolactin, or ACTH at physiologically relevant concentrations in published animal models, making it a valuable tool for isolating the GH axis in laboratory research.

2. Why the Two Are Studied Together

CJC-1295 and Ipamorelin act on two distinct but complementary receptors that both converge on GH release. Preclinical literature describes their combined use as producing a greater, more physiological GH pulse than either peptide alone via three overlapping mechanisms:

  • Amplitude: GHRH-R activation increases the amount of GH released per pulse.
  • Frequency: GHS-R1a activation via Ipamorelin suppresses somatostatin tone, permitting more frequent pulses.
  • Somatotroph priming: Chronic low-dose GHRH signaling upregulates somatotroph population and GH stores, which a ghrelin mimetic can then release.

3. Common Research Protocols

The following reflects protocols described in published preclinical and in-vitro literature. It is provided for informational and academic reference only and is not a use, dosing, or human-administration recommendation.

ParameterTypical Range in Literature
ReconstitutionBacteriostatic water, 2–3 mL per 5 mg vial
CJC-1295 (no DAC)100 mcg equivalent, 1–3× daily
Ipamorelin100–300 mcg equivalent per pulse
TimingPre-sleep pulse commonly modeled to align with endogenous GH peak
StorageLyophilized: 2–8 °C. Reconstituted: refrigerated, protected from light.

4. Handling & Quality Considerations

  • Verify purity (≥ 99%) and identity via third-party HPLC and mass-spectrometry certificates of analysis before use in any assay.
  • Avoid repeated freeze–thaw cycles; aliquot reconstituted material.
  • Endotoxin-sensitive assays require additional testing beyond a standard identity/purity COA.

Related Products

Vertex Peptides supplies research-grade CJC-1295 and Ipamorelin, individually and as pre-blended vials, each with a third-party COA.

Research Use Only. The information above is a technical summary of published preclinical literature. Vertex Peptides products are sold strictly for in-vitro laboratory and research applications and are not intended for human or veterinary use, diagnosis, or treatment.
V
Vertex Peptides

A research supply company providing lyophilized peptides and reference compounds to laboratories, with third-party testing documentation on every batch.

For Research Use Only

Company

Policies

Contact

  • vertextpeptidebuynow@outlook.com
  • (916) 477-3947
  • Sacramento, California

Disclaimer: All products sold by Vertex Peptides are intended strictly for in-vitro laboratory and preclinical research by qualified professionals. Products are not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. No medical claims are made regarding any product listed on this site.

© 2026 Vertex Peptides. All rights reserved.